AmMax Bio to Present at the Oppenheimer Healthcare Private Company Showcase
27 Septiembre 2024 - 7:33AM
AmMax Bio, Inc., a private clinical-stage biopharmaceutical company
developing innovative therapeutics in oncology, today announced
that it will present at the Oppenheimer Healthcare Private Company
Showcase in New York City on Tuesday, October 1, 2024. Andrew
Sauter, Chief Financial Officer, will present a company overview at
2:25 pm ET and will be available for 1x1 investor meetings, which
can be requested through Oppenheimer.
AmMax is advancing an innovative oncology
pipeline that leverages the advantages of CSF1R target engagement
to create new treatments with clinically meaningful
differentiation. The Company’s AMB-066 program is on track to
initiate enrollment in a phase 2 proof of concept study in the
fourth quarter to treat patients with colorectal cancer with
minimal residual disease (CRC MRD).
About Colorectal Cancer with Minimal Residual
Disease
An estimated 20,000 patients annually in the US
have CRC MRD after definitive therapy including curative intent
surgery with or without neo-adjuvant and/or adjuvant therapies. CRC
MRD is defined as a patient with positive circulating tumor DNA
(ctDNA+) and without radiographic evidence of disease. These
patients are at a much higher risk to relapse and develop
metastasis to other organs, primarily the liver. Currently there
are no approved therapies for CRC MRD and standard of care is
simply observation.
About AMB-066AMB-066 uses a
potent monoclonal antibody targeting the colony stimulating factor
1 receptor (CSF1R) to treat patients with colorectal cancer with
minimal residual disease (CRC MRD). The antibody has been tested in
~200 patients and healthy subjects across five clinical trials for
other indications via intravenous, intra-articular, and
subcutaneous injections, and has been shown to be generally safe
and well tolerated in all studies.
About AmMax Bio Inc.
AmMax Bio, founded by Larry Hsu, PhD in 2020,
is a clinical-stage biotechnology company focused on the
development of innovative therapeutics for cancer patients. AmMax
has built a robust pipeline addressing significant unmet needs and
large commercial opportunities based on its CSF1R-targeting
platform. The Company’s pipeline includes AMB-066, for treating
patients with colorectal cancer with minimal residual disease (CRC
MRD), AMB-051, a locally administered injection for treating
patients with tenosynovial giant cell tumor (TGCT), and AMB-104, a
novel antibody-drug conjugate for the treatment of acute myeloid
leukemia (AML). For more information, please visit the company’s
website at www.AmMaxBio.com.
Contact
AmMax Bio, Inc.
Andrew Sauter, CFO
Email: andrewsauter@ammaxbio.com
Tel: 650-787-3777